# CNPLE Cram V2 — Parity Batch 41B Clinical Second Pass

Date: 2026-08-09
Scope: `41b-diagnostics-testing-interpretation-parity.json`
Result: **PASS — clinical authoring second pass**

## Exact identity contract

- `np-nuclear-medicine-studies`
- `np-screening-test-interpretation`
- `np-diagnostic-test-sensitivity-and-specificity`
- `np-point-of-care-testing`
- `np-microbiology-test-interpretation`
- `np-immunology-test-interpretation`
- `np-genetic-testing-considerations`
- `np-tumor-marker-interpretation`

## Clinical review

- Nuclear medicine: functional uptake is interpreted in tracer/indication context; uptake is not equated with malignancy.
- Screening: asymptomatic screening is separated from symptomatic diagnostic pathways and predictive values are linked to prevalence.
- Sensitivity/specificity: PPV/NPV and pretest probability are distinguished from intrinsic test characteristics.
- Point-of-care testing: rapid turnaround does not remove device/operator/quality-control limits or confirmatory requirements.
- Microbiology: active infection is separated from colonization, contamination and past exposure; specimen quality and syndrome remain authoritative.
- Immunology: disease phenotype precedes broad autoantibody testing; isolated ANA/other antibodies are not used as diagnoses.
- Genetics: VUS is explicitly non-actionable as pathogenic evidence; family history and pre/post-test counselling are core.
- Tumor markers: no general occult-cancer screening panel; marker trends are adjunctive only in validated disease-specific contexts.

## Canadian source refresh

Rechecked 2026-08-09 against Canadian Association of Radiologists Referral Guidelines, Canadian oncology/Choosing Wisely practice, PHAC antimicrobial stewardship principles, Choosing Wisely Canada laboratory/rheumatology recommendations, and Genetics Education Canada — Knowledge Organization (GECKO) 2025 genomic-test-results guidance and 2026 Canadian genomics referral resources.

## Publication boundary

Clinical authoring PASS only. Global parse/count/ID validation, exact current Full identity, source anchors, Bottom Line evidence, exactly three eligible Quick Checks, runtime certification, learner render QA, merge and deployment remain downstream fail-closed gates.
